Program

KEYNOTE SESSION

6:30 p.m.-8:00 p.m.

EMT under review
Jean Paul Thiery, Institute of Molecular and Cell Biology, A*STAR, Singapore

EMT and angiogenesis in cancer metastasis
Eric G. Neilson, Vanderbilt University, Nashville, TN

POSTER SESSION A AND DESSERT RECEPTION

8:15 p.m.-10:15 p.m.

SESSION 1
EMT AND MET IN NORMAL DEVELOPMENT

Chairperson: Paolo M. Comoglio, Institute for Cancer Research-Candiolo, Turin, Italy
8:00 a.m.-10:00 a.m.

SoxB transcription factors control Snail expression and EMT in developing embryos and cancer cells
M. Angela Nieto, Instituto de Neurociencias, San Juan de Alicante, Spain

Regulation of EMT by integrins
Harold A. Chapman, University of California, San Francisco, CA

The role of EMT and EndMT in cancer progression and fibrosis
Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA

Developmental EMTs as a model for pathological EMTs
Carole B. LaBonne, Northwestern University, Evanston, IL

SESSION 2
EMT AND MET IN CANCER DEVELOPMENT

Chairperson: M. Angela Nieto, Instituto de Neurociencias, San Juan de Alicante, Spain
10:30 a.m.-12:30 p.m.

The Six1 homeoprotein as a regulator of TGF-beta signaling, EMT, and cancer stem cells
Heide L. Ford, University of Colorado Health Sciences Center, Aurora, CO

Tumor invasion and metastasis: EMT and cancer stem cells
Thomas Brabletz, University of Freiburg, Freiburg, Germany

Insights into the human breast cancer EMT from established cell lines
Erik W. Thompson, St. Vincent's Institute and University of Melbourne, Fitzroy, Australia

Evidence for linking EMT to clinical outcome: E-cadherin expression in non-small cell lung cancer (NSCLC) predicts clinical benefits from erlotinib therapy
David W. Sternberg, OSI Pharmaceuticals, Inc., Farmingdale, NY

SESSION 3
SIGNALS INDUCING EMT

Chairperson: Margaret C. Frame, Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom
2:00 p.m.-4:00 p.m.

Tyrosine kinases, EMT, and cancer
Margaret C. Frame

Invasive growth: A genetic program driven by the MET oncogene
Paolo M. Comoglio, Institute for Cancer Research-Candiolo, Turin, Italy

Actions of angiogenesis inhibitors on tumor blood vessels and tumor cells
Donald M. McDonald, University of California, San Francisco, CA

The T-box transcription factor Brachyury induces epithelial to mesenchymal transition in human epithelial tumor cells*
Romaine Fernando, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Comparison of in vitro and in vivo epithelial to mesenchymal transition following inducible expression of Snail or Zeb-1 in a human non-small cell lung cancer line*
Maryland Rosenfeld-Franklin, OSI Pharmaceuticals, Melville, NY

SESSION 4
SIGNALING PATHWAYS DRIVING EMT

Chairperson: Donald M. McDonald, University of California, San Francisco, CA
4:30 p.m.-6:30 p.m.

The tumor suppressor pathways TGFß and LKB1 control EMT
Aristidis Moustakas, Ludwig Institute for Cancer Research, Uppsala, Sweden

The Cain and Abl of EMT and TGF-β signaling in mammary epithelial cells
William P. Schiemann, University of Colorado Denver, Aurora, CO

FGFR1 and Wnt-mediated EMT and stem cell proliferation
David M. Spencer, Baylor College of Medicine, Houston, TX

Circulating tumor cells from patients with metastatic breast and prostate cancer express vimentin and n-cadherin*
Andrew J. Armstrong, Duke University, Durham, NC

The Src tyrosine kinase downregulates C/EBP delta protein expression via the SIAH2 E3 ubiquitin ligase to maintain motility of breast tumor cells*
Tapasree Roy Sarkar, National Cancer Institute, Bethesda, MD

POSTER SESSION B AND RECEPTION

6:30 p.m.-8:30 p.m.

SESSION 5
EMT IN INVASION AND METASTASIS

Chairperson: Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA
8:00 a.m.-10:00 a.m.

Molecular mechanisms of EMT contributing to invasion and metastasis in breast tumors
John S. Condeelis, Albert Einstein College of Medicine, Bronx, NY

The role of alternate isoforms in EMT and metastasis
Frank B. Gertler, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA

The functional significance of changes in cytoskeletal intermediate filament composition during the Epithelial to Mesenchymal Transition: Vimentin is more than a biomarker
Robert D. Goldman, Northwestern University, Chicago, IL

Insurance against EMT: MiR-200c directly targets multiple nonepithelial genes*
Erin Howe, University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO

EMT-induced tubulin detyrosination can be inhibited with parthenolide, reducing microtentacles and the lung retention of circulating breast tumor cells*
Stuart S. Martin, University of Maryland, Baltimore, MD

SESSION 6
EMT AND CANCER STEM CELLS

Chairperson: Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA
10:30 a.m.-12:30 p.m.

Stem cells and cancer: Two faces of self-renewal
Michael F. Clarke, Stanford University School of Medicine, Stanford, CA

The epithelial-mesenchymal transition and the stem-cell state
Robert A. Weinberg

Residual tumors after therapy display mesenchymal and tumor-initiating properties
Jenny Chang, Baylor College of Medicine, Houston, TX

Prosurvival signaling network switching through epithelial-mesenchymal transitions
John D. Haley, OSI Pharmaceuticals, Inc., Farmingdale, NY

DEPARTURE